Premium
Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV‐IG prophylaxis: A monocentric retrospective analysis
Author(s) -
Gilioli Andrea,
Messerotti Andrea,
Bresciani Paola,
Cuoghi Angela,
Pioli Valeria,
Colasante Corrado,
Bettelli Francesca,
Giusti Davide,
Forghieri Fabio,
Potenza Leonardo,
Donatelli Francesca,
Giubbolini Rachele,
Galassi Laura,
Marasca Roberto,
Banchelli Federico,
D'Amico Roberto,
Pecorari Monica,
Gennari William,
Trenti Tommaso,
Comoli Patrizia,
Luppi Mario,
Narni Franco
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26861
Subject(s) - cytomegalovirus , medicine , seroconversion , incidence (geometry) , hematopoietic stem cell transplantation , cohort , immunology , virology , betaherpesvirinae , population , herpesviridae , transplantation , viral disease , virus , physics , environmental health , optics
Abstract Human cytomegalovirus (CMV) represents the most common viral infection after hematopoietic stem cell transplant (HSCT), mainly occurring as reactivation from latency in seropositive patients, with a different prevalence based on the extent and timing of seroconversion in a specific population. Here, we retrospectively analyzed a cohort of patients who underwent HSCT at our Institution between 2013 and 2018, all of whom were prophylactically treated with CMV‐IG (Megalotect Biotest®), to define the incidence and clinical outcomes of CMV reactivation and clinically significant infection. CMV infection occurred in 69% of our patient series, mainly resulting from reactivation, and CMV clinically significant infection (CS‐CMVi) occurred in 48% of prophylactically treated patients. CMV infection and CS‐CMVi impacted neither on relapse incidence nor on overall survival nor on relapse‐free survival. Moreover, a very low incidence of CMV end‐organ disease was documented. CMV‐IG used alone as prophylactic therapy after HSCT does not effectively prevent CMV reactivation.